Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
SLP 
Simulations Plus Inc (SLP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/26/2026: SLP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $24.67
1 Year Target Price $24.67
| 5 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 237.93M USD | Price to earnings Ratio - | 1Y Target Price 24.67 |
Price to earnings Ratio - | 1Y Target Price 24.67 | ||
Volume (30-day avg) 6 | Beta 1.13 | 52 Weeks Range 11.16 - 36.45 | Updated Date 02/26/2026 |
52 Weeks Range 11.16 - 36.45 | Updated Date 02/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -81.66% | Operating Margin (TTM) 3.87% |
Management Effectiveness
Return on Assets (TTM) 2.79% | Return on Equity (TTM) -41.21% |
Valuation
Trailing PE - | Forward PE 21.64 | Enterprise Value 202799168 | Price to Sales(TTM) 3.02 |
Enterprise Value 202799168 | Price to Sales(TTM) 3.02 | ||
Enterprise Value to Revenue 2.58 | Enterprise Value to EBITDA 14.11 | Shares Outstanding 20146585 | Shares Floating 16643900 |
Shares Outstanding 20146585 | Shares Floating 16643900 | ||
Percent Insiders 17.32 | Percent Institutions 85.62 |
Upturn AI SWOT
Simulations Plus Inc
Company Overview
History and Background
Simulations Plus Inc. was founded in 1996. The company has grown by developing and acquiring expertise in pharmacometrics, pharmacokinetic/pharmacodynamic (PK/PD) modeling, and drug discovery and development software. Key milestones include the launch of its GastroPlusu2122 software and its consistent focus on providing predictive modeling solutions to the pharmaceutical and biotechnology industries.
Core Business Areas
- Drug Discovery and Development Software: Simulations Plus develops and licenses sophisticated software used by pharmaceutical and biotechnology companies to model and predict the behavior of drug candidates in the human body. This includes predicting absorption, distribution, metabolism, excretion, and toxicity (ADMET).
- Contract Research Services: The company also offers contract research services, leveraging its software and scientific expertise to perform specialized modeling and simulation studies for clients, assisting them in making informed decisions throughout the drug development process.
Leadership and Structure
Simulations Plus operates with a dedicated leadership team comprising a CEO, CFO, and heads of various departments such as R&D, Sales, and Operations. The organizational structure is designed to foster innovation in its software development and efficient delivery of its research services.
Top Products and Market Share
Key Offerings
- Description: A leading software tool for simulating the gastrointestinal absorption and disposition of drugs. It helps researchers predict oral drug bioavailability and optimize drug formulation. It's a cornerstone product for many pharmaceutical R&D departments. Competitors include other specialized PK/PD modeling software providers and in-house modeling capabilities.
- Market Share Data: While specific market share percentages are not publicly disclosed, GastroPlus is considered a market leader in its niche. The number of users is in the hundreds across leading pharmaceutical companies.
- Product Name 1: GastroPlusu2122
- Revenue Contribution: A significant portion of the company's software revenue is derived from GastroPlus and related products.
- Description: This software uses quantitative structure-activity relationship (QSAR) models to predict the ADMET properties of drug candidates early in the discovery process. This helps to de-risk drug development and reduce the need for costly in-vitro and in-vivo testing. Competitors include other QSAR modeling software and AI-driven drug discovery platforms.
- Market Share Data: Another key product with a substantial user base in the pharmaceutical industry. Its adoption is growing with the increasing demand for early-stage drug property prediction.
- Product Name 2: ADMET Predictoru2122
- Revenue Contribution: Contributes substantially to the company's software licensing revenue.
- Description: A powerful nonlinear mixed-effects modeling software used for population pharmacokinetics and pharmacodynamics (PopPK/PD) analysis. Essential for understanding drug behavior in diverse patient populations. Competitors include Monolix, NONMEM, and SAS.
- Market Share Data: A widely adopted software in the pharmacometrics field, with a significant installed base among clinical pharmacologists and biostatisticians.
- Product Name 3: Phoenix NLMEu2122
- Revenue Contribution: A strong revenue generator, especially within its established customer base.
Market Dynamics
Industry Overview
Simulations Plus operates within the pharmaceutical and biotechnology R&D support services and software market. This industry is characterized by a continuous need for innovative tools and services to accelerate drug discovery and development, reduce costs, and improve success rates. The rise of precision medicine and complex biologics further fuels the demand for advanced modeling and simulation capabilities.
Positioning
Simulations Plus is positioned as a specialized provider of advanced modeling and simulation software and services for drug discovery and development. Its competitive advantages lie in its scientifically robust, validated software, deep domain expertise, strong customer relationships, and a consistent track record of innovation. The company focuses on niche but critical areas within the drug development pipeline.
Total Addressable Market (TAM)
The TAM for drug discovery and development software and services is substantial and growing, driven by global pharmaceutical R&D spending. While exact figures vary, it is estimated to be in the billions of dollars. Simulations Plus is well-positioned within its specific niches, capturing a significant portion of the demand for its specialized solutions.
Upturn SWOT Analysis
Strengths
- Proprietary, scientifically validated software platforms.
- Deep domain expertise in pharmacometrics and drug development simulation.
- Strong customer base within the pharmaceutical and biotechnology industries.
- Recurring revenue model from software licenses and maintenance.
- Established reputation for accuracy and reliability.
- Agile development and continuous improvement of software.
Weaknesses
- Relatively smaller company size compared to large software providers.
- Reliance on a few key software products.
- Potential for long sales cycles in enterprise software.
- Need to continuously invest in R&D to stay ahead of technological advancements.
Opportunities
- Growing adoption of AI and machine learning in drug discovery, which can be integrated with existing platforms.
- Expansion into emerging markets with increasing pharmaceutical R&D investment.
- Development of new software modules or solutions for biologics and other complex modalities.
- Strategic acquisitions to broaden product portfolio or market reach.
- Increased outsourcing of R&D activities by pharmaceutical companies.
- Leveraging cloud-based solutions for wider accessibility.
Threats
- Increased competition from other specialized software vendors and in-house development by large pharma.
- Changes in regulatory landscapes that could impact drug development processes.
- Economic downturns affecting R&D budgets of pharmaceutical companies.
- Rapid technological advancements by competitors that could make existing solutions obsolete.
- Cybersecurity threats to proprietary software and client data.
Competitors and Market Share
Key Competitors
- Certara, Inc. (global leader in biosimulation)
- Optibrium Ltd. (drug discovery software)
- Schru00f6dinger, Inc. (computational drug discovery)
- ACSL (Advanced Computational Solutions, Inc.) (software and services)
- Smaller specialized modeling and simulation software providers.
Competitive Landscape
Simulations Plus holds a strong position in its niche markets, particularly with its established products like GastroPlus and Phoenix NLME. Its key advantage is its scientific depth and validated models. However, larger, more diversified companies like Certara and Schru00f6dinger have broader platforms and greater resources, posing significant competitive challenges. The market is also fragmented with numerous smaller, specialized players.
Growth Trajectory and Initiatives
Historical Growth: Simulations Plus has experienced a consistent upward trajectory in revenue and profitability over the past decade, driven by the increasing adoption of its predictive modeling software and expansion of its service offerings. The company has successfully grown its customer base and diversified its revenue streams.
Future Projections: Analyst projections generally indicate continued revenue and earnings growth for Simulations Plus, supported by the expanding use of simulation in drug development, its strong product pipeline, and potential new market entries. Growth is expected to be driven by both software sales and contract research services.
Recent Initiatives: Recent initiatives likely include the enhancement of existing software with new features, the development of AI-driven capabilities, and potential expansion into related areas of preclinical and clinical research support. The company also likely focuses on strategic partnerships and market penetration in underserved regions.
Summary
Simulations Plus is a robust player in the niche drug discovery and development simulation software market. Its strengths lie in its scientifically validated products and deep expertise, leading to consistent revenue and profit growth. However, it faces challenges from larger competitors and the need for continuous innovation. Continued investment in R&D and strategic partnerships will be crucial for sustained success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Financial news and data providers (e.g., Yahoo Finance, Bloomberg, Refinitiv)
- Industry research reports
- Company investor relations materials
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is estimated. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Financial data is based on publicly available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Simulations Plus Inc
Exchange NASDAQ | Headquaters Research Triangle Park, NC, United States | ||
IPO Launch date 1997-06-18 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 212 | Website https://www.simulations-plus.com |
Full time employees 212 | Website https://www.simulations-plus.com | ||
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.